Sulzer Medica reports strong first quarter:
This article was originally published in Clinica
Swiss company Sulzer Medica has seen sales rise 21% to SwFr 346 million ($235 million) in the first quarter. Adjusted for beneficial currency moves, the rise is 9%. The cardiovascular prosthesis division performed best, increasing 33% to SwFr 52 million, followed by pacemakers, up 22% to SwFr 112 million, and orthopaedics, up 17% to SwFr 184 million. In the summer, Sulzer Medica is planning to offer a quarter of its shares to the public in the US and Switzerland.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.